Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to $6.7 million.

  • SAB Biotherapeutics' Gains from Investment Securities rose 11797.62% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 11797.62%. This contributed to the annual value of $3.0 million for FY2024, which is 19399.64% up from last year.
  • SAB Biotherapeutics' Gains from Investment Securities amounted to $6.7 million in Q3 2025, which was up 11797.62% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Gains from Investment Securities registered a high of $9.9 million during Q2 2023, and its lowest value of -$1.7 million during Q2 2022.
  • For the 5-year period, SAB Biotherapeutics' Gains from Investment Securities averaged around $3.2 million, with its median value being $2.9 million (2025).
  • As far as peak fluctuations go, SAB Biotherapeutics' Gains from Investment Securities crashed by 18880.36% in 2022, and later skyrocketed by 1302042.04% in 2023.
  • SAB Biotherapeutics' Gains from Investment Securities (Quarter) stood at $3.9 million in 2021, then plummeted by 100.94% to -$36586.0 in 2022, then surged by 13020.42% to $4.7 million in 2023, then tumbled by 51.21% to $2.3 million in 2024, then soared by 192.63% to $6.7 million in 2025.
  • Its Gains from Investment Securities was $6.7 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.0 million in Q1 2025.